Story
Sanofi to Pay Regeneron Up to $8 Billion to Expand Dupixent Partnership

French pharmaceutical giant Sanofi announced it will pay its U.S. partner Regeneron up to $8 billion to expand their highly successful drug development partnership. The deal, which includes a $1 billion upfront payment, adds four new experimental antibodies to the collaboration responsible for the blockbuster drug Dupixent.
Deal Structure and Financials
Under the terms of the expanded agreement, Sanofi will provide Regeneron with an immediate $1 billion payment, with an additional $7 billion contingent on achieving certain development, regulatory, and sales milestones. For the new assets, the companies will share costs and profits equally, though the existing profit-sharing terms for Dupixent remain unchanged.
The agreement outlines a clear division of responsibilities: Regeneron will lead research and development, while Sanofi will spearhead global commercialization efforts. The companies also noted they have settled previous litigation related to their collaboration. Additionally, Regeneron has an option to co-develop Sanofi's experimental drug lunsekimig following the completion of its late-stage trials.
Strategic Rationale and Market Reaction
AdSanofi described the deal as a crucial first step in rebuilding its drug pipeline ahead of Dupixent's eventual loss of patent protection. The four new antibodies target the same inflammatory immune signals as Dupixent but are designed for longer-lasting effects in the body, potentially treating conditions like eczema.
Investors reacted positively to the news, with Sanofi's shares rising 2% in early trading on Thursday, according to Reuters. Analysts at Jefferies noted that while the assets are early-stage, the expansion "should be viewed positively, as it signals the new CEO’s proactive focus on the most important yet addressable uncertainties investors face."
Context of the Partnership
The collaboration between Sanofi and Regeneron has been highly lucrative, driven by the success of Dupixent. The drug, which treats inflammatory conditions across nine approved indications, is currently used by more than 1.5 million patients globally. This expansion builds on a proven model of co-development that has already yielded a major commercial success.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.